Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GARDASIL 9 in Post Solid Organ Transplant Patients
NCT05557370Phase 4
Key facts
- Status
- Active, not recruiting
- Start
- Jun 2023
- Primary completion
- Dec 2028
- Countries
- 1
- Sponsor
- Medical College of Wisconsin
- Modality
- Vaccines & Immunotherapeutics
- Conditions
- human papillomavirus infection
01
Overview
Phase 4, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Medical College of Wisconsin. Primary endpoint: Geometric Mean Titers of Anti-HPV antibodies at 24 months. Started Jun 2023; status: active, not recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Interventional
Patients receive 3-dose 9vHPV vaccination (GARDASIL 9)
03
Who it enrols
Adults 18-45 years old, at least 6 months post-solid-organ transplant, who have not received GARDASIL 9.
04
Endpoints
Primary
Geometric Mean Titers of Anti-HPV antibodies
Beyond the preview
Go deeper on NCT05557370.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05557370.